芪参还五胶囊对气血亏虚型帕金森病患者UPDRS评分及平衡能力的影响

Effect of Qishenhuanwu capsule on UPDRS scores and balance ability of Parkinson′s disease patients with Qi and Blood Deficiency

摘要:

目的 探讨芪参还五胶囊治疗气血亏虚型帕金森病(PD)患者的疗效及其对患者统一帕金森病评定量表(UPDRS)评分和平衡能力的影响。方法 选择2018年3月至2019年12月河北省沧州中西医结合医院住院治疗的气血亏虚型PD患者130例,按照药物治疗方式不同分为2组,每组患者65例。对照组行单纯多巴丝肼片治疗,芪参还五胶囊组在对照组基础上加用芪参还五胶囊治疗,2组均治疗3个月。比较治疗前和治疗后3个月2组治疗有效率、中医症候积分、UPDRS评分、Berg平衡量表(SSB)评分、PD生存质量调查表(PDQ-39)评分及不良反应情况。采用SPSS 23.0软件进行数据分析。根据数据类型,组间比较分别采用t检验及χ²检验。结果 治疗后3个月,芪参还五胶囊组总有效率为92.31%(60/65),高于对照组的80.00%(52/65),差异有统计学意义(P＜0.05)；2组组内中医症候积分、UPDRSⅡ评分、UPDRSⅢ评分、PDQ-36评分均下降,BBS评分升高(均P＜0.05)；芪参还五胶囊组中医症候积分、UPDRSⅡ评分、UPDRSⅢ评分均优于对照组(均P＜0.05)。芪参还五胶囊组不良反应率为3.08%(2/65),对照组为7.69%(5/65),差异无统计学意义(P＞0.05)。结论 芪参还五胶囊治疗气血亏虚型帕金森病病效果显著,不良反应小,可改善患者日常活动、运动功能及平衡功能,提高患者的生活质量。

Abstract:

Objective To investigate the efficacy of Qishenhuanwu capsule in treatment of Parkinson′s disease (PD) patients with Qi and Blood Deficiency and its effect on Unified Parkinson′s disease rating scale (UPDRS) scores and balance ability. Methods A total of 130 PD patients with Qi and Blood Deficiency treated in our hospital from March 2018 to December 2019 were recruited in this study, and were divided into control group (n=65, simple Basizide tablet) and Qishenhuanwu treatment group (n=65, Qishenhuanwu capsule plus Basizide tablet). All of the patients were treated for 3 months. The treatment efficiency, traditional Chinese medicine (TCM) symptom score, UPDRS score, Berg Balance Scale score, the Parkinson′s disease questionnaire-39 score, and adverse reactions were compared before and after treatment between 2 groups. SPSS statistics 23.0 was used for statistical analysis. Data comparison between two groups was perfomed using t test or χ² test depending on data type. Results In 3 months after treatment, the total effective rate was 92.31% (60/65) in the Qishenhuanwu treatment group, significantly higher than that of the control group [80.00% (52/65), P<0.05]. After treatment, the TCM symptom score, UPDRSⅡ score, UPDRSⅢ score, and PDQ-36 score were all decreased, and the BBS score were increased in both groups (all P<0.05). The Qishenhuanwu group obtained better TCM symptom score, UPDRSⅡ score, and UPDRSⅢ score than the control group (all P＜0.05). The adverse reaction rate was 3.08% (2/65) in the Qishenhuanwu group and 7.69% (5/65) in the control group, but there was no statistical difference between them (P>0.05). Conclusion Qishenhuanwu capsule shows significant effectiveness in treatment of PD patients with Qi and Blood Deficiency, with less adverse reactions, and can improve daily activities, motor function, balance function and the life quality of the patients.